Efficacy of a saponin-adjuvanted inactivated respiratory syncytial virus vaccine in calves
Identifieur interne : 000696 ( Pmc/Checkpoint ); précédent : 000695; suivant : 000697Efficacy of a saponin-adjuvanted inactivated respiratory syncytial virus vaccine in calves
Auteurs : John A. Ellis ; Keith H. West ; Cheryl Waldner ; Carrie RhodesSource :
- The Canadian Veterinary Journal [ 0008-5286 ] ; 2005.
Abstract
The objective of this study was to determine whether a commercially available, saponin-adjuvanted, inactivated bovine respiratory syncytial virus (BRSV) vaccine would protect calves from experimental infection with virulent BRSV. This was a randomized controlled trial comprising 14, 8- to 9-week-old calves seronegative for BRSV. Group 1 calves (
Url:
PubMed: 15825518
PubMed Central: 1082864
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:1082864Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy of a saponin-adjuvanted inactivated respiratory syncytial virus vaccine in calves</title><author><name sortKey="Ellis, John A" sort="Ellis, John A" uniqKey="Ellis J" first="John A." last="Ellis">John A. Ellis</name></author><author><name sortKey="West, Keith H" sort="West, Keith H" uniqKey="West K" first="Keith H." last="West">Keith H. West</name></author><author><name sortKey="Waldner, Cheryl" sort="Waldner, Cheryl" uniqKey="Waldner C" first="Cheryl" last="Waldner">Cheryl Waldner</name></author><author><name sortKey="Rhodes, Carrie" sort="Rhodes, Carrie" uniqKey="Rhodes C" first="Carrie" last="Rhodes">Carrie Rhodes</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">15825518</idno><idno type="pmc">1082864</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1082864</idno><idno type="RBID">PMC:1082864</idno><date when="2005">2005</date><idno type="wicri:Area/Pmc/Corpus">000425</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000425</idno><idno type="wicri:Area/Pmc/Curation">000425</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000425</idno><idno type="wicri:Area/Pmc/Checkpoint">000696</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000696</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Efficacy of a saponin-adjuvanted inactivated respiratory syncytial virus vaccine in calves</title><author><name sortKey="Ellis, John A" sort="Ellis, John A" uniqKey="Ellis J" first="John A." last="Ellis">John A. Ellis</name></author><author><name sortKey="West, Keith H" sort="West, Keith H" uniqKey="West K" first="Keith H." last="West">Keith H. West</name></author><author><name sortKey="Waldner, Cheryl" sort="Waldner, Cheryl" uniqKey="Waldner C" first="Cheryl" last="Waldner">Cheryl Waldner</name></author><author><name sortKey="Rhodes, Carrie" sort="Rhodes, Carrie" uniqKey="Rhodes C" first="Carrie" last="Rhodes">Carrie Rhodes</name></author></analytic><series><title level="j">The Canadian Veterinary Journal</title><idno type="ISSN">0008-5286</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Abstract</title><p>The objective of this study was to determine whether a commercially available, saponin-adjuvanted, inactivated bovine respiratory syncytial virus (BRSV) vaccine would protect calves from experimental infection with virulent BRSV. This was a randomized controlled trial comprising 14, 8- to 9-week-old calves seronegative for BRSV. Group 1 calves (<italic>n</italic> = 8) were not vaccinated and group 2 calves (<italic>n</italic> = 6) were vaccinated on days 0 and 19 with an inactivated BRSV vaccine. All calves were challenged with virulent BRSV on day 46. Clinical signs, arterial PO<sub>2</sub>, and immune responses were monitored after challenge. Calves were euthanatized on day 54 (8 d after challenge) and lungs were examined for lesions. Vaccination elicited increases in BRSV-specific immunoglobulin (Ig) G and virus neutralizing antibody titers. Challenge with BRSV resulted in severe respiratory tract disease and extensive pulmonary lesions in control calves, but no signs of clinical disease and minimal or no pulmonary lesions in vaccinated calves. Arterial blood oxygen values on day 53 (7 d after challenge) in control calves were significantly lower than those in vaccinated calves, which remained within normal limits. Control calves shed BRSV for several days after challenge, whereas BRSV was not detected on deep nasal swabs from vaccinated calves. In summary, the results indicated that this inactivated BRSV vaccine provided clinical protection from experimental infection with virulent virus 27 d after vaccination and significantly decreased the prevalence and severity of pulmonary lesions. Efficacy was similar to that reported for other commercial inactivated and modified-live BRSV vaccines.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Can Vet J</journal-id><journal-title>The Canadian Veterinary Journal</journal-title><issn pub-type="ppub">0008-5286</issn><publisher><publisher-name>Canadian Veterinary Medical Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15825518</article-id><article-id pub-id-type="pmc">1082864</article-id><article-id pub-id-type="publisher-id">pg155</article-id><article-categories><subj-group subj-group-type="heading"><subject>Scientific</subject><subj-group><subject>Articles</subject></subj-group></subj-group></article-categories><title-group><article-title>Efficacy of a saponin-adjuvanted inactivated respiratory syncytial virus vaccine in calves</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name><surname>Ellis</surname><given-names>John A.</given-names></name></contrib><contrib contrib-type="author" xlink:type="simple"><name><surname>West</surname><given-names>Keith H.</given-names></name></contrib><contrib contrib-type="author" xlink:type="simple"><name><surname>Waldner</surname><given-names>Cheryl</given-names></name></contrib><contrib contrib-type="author" xlink:type="simple"><name><surname>Rhodes</surname><given-names>Carrie</given-names></name></contrib></contrib-group><aff>Departments of Veterinary Microbiology (Ellis, Rhodes); Herd Medicine (Waldner), Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Saskatchewan; Prairie Diagnostic Services, Saskatoon, Saskatchewan S7N 5B4 (West).</aff><author-notes><corresp>Address all correspondence and reprint requests to Dr. John Ellis.</corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2005</year></pub-date><volume>46</volume><issue>2</issue><fpage>155</fpage><lpage>162</lpage><copyright-statement>© Copyright and/or publishing rights held by the Canadian Veterinary Medical Association</copyright-statement><copyright-year>2005</copyright-year><abstract><title>Abstract</title><p>The objective of this study was to determine whether a commercially available, saponin-adjuvanted, inactivated bovine respiratory syncytial virus (BRSV) vaccine would protect calves from experimental infection with virulent BRSV. This was a randomized controlled trial comprising 14, 8- to 9-week-old calves seronegative for BRSV. Group 1 calves (<italic>n</italic> = 8) were not vaccinated and group 2 calves (<italic>n</italic> = 6) were vaccinated on days 0 and 19 with an inactivated BRSV vaccine. All calves were challenged with virulent BRSV on day 46. Clinical signs, arterial PO<sub>2</sub>, and immune responses were monitored after challenge. Calves were euthanatized on day 54 (8 d after challenge) and lungs were examined for lesions. Vaccination elicited increases in BRSV-specific immunoglobulin (Ig) G and virus neutralizing antibody titers. Challenge with BRSV resulted in severe respiratory tract disease and extensive pulmonary lesions in control calves, but no signs of clinical disease and minimal or no pulmonary lesions in vaccinated calves. Arterial blood oxygen values on day 53 (7 d after challenge) in control calves were significantly lower than those in vaccinated calves, which remained within normal limits. Control calves shed BRSV for several days after challenge, whereas BRSV was not detected on deep nasal swabs from vaccinated calves. In summary, the results indicated that this inactivated BRSV vaccine provided clinical protection from experimental infection with virulent virus 27 d after vaccination and significantly decreased the prevalence and severity of pulmonary lesions. Efficacy was similar to that reported for other commercial inactivated and modified-live BRSV vaccines.</p></abstract><trans-abstract xml:lang="FR"><p><bold>Résumé — Efficacité d’un vaccin inactif à adjuvant de saponine contre le virus respiratoire syncytial chez le veau.</bold> L’objectif de cette étude était de déterminer si un vaccin inactif à adjuvant de saponine contre le virus respiratoire syncytial bovin (VRSB), disponible dans le commerce, pouvait protéger les veaux contre une infection expérimentale par le VRSB virulent. Cette expérience contrôlée comprenait 14 veaux séronégatifs répartis au hasard et âgés de 8 à 9 semaines. Les veaux du groupe 1 (<italic>n</italic> = 8) n’ont pas été vaccinés et ceux du groupe 2 (<italic>n</italic> = 6) ont été vaccinés aux jours 0 et 19 avec un vaccin inactivé contre le VRSB. Tous les veaux ont été infectés avec du VRSB virulent au jour 46. Les signes cliniques, le PO<sub>2</sub> artériel et les réponses immunitaires ont été enregistrés après l’infection. Les veaux ont été euthanasiés au jour 54 (8 jours après l’infection) et les poumons ont été examinés dans le but d’y observer des lésions. La vaccination a causé une augmentation du titre des immunoglobulines spécifiques au VRSB (Ig)G et des anticorps neutralisants du virus. L’infection par le VRSB a causé une grave maladie du tractus respiratoire et des lésions pulmonaires extensives chez les veaux témoins, mais aucun signe de maladie clinique et pas de lésions ou des lésions minimes seulement chez les veaux vaccinés. Les valeurs de l’oxygène du sang artériel au jour 53 (7 jours après l’infection) chez les veaux témoins étaient significativement plus basses que celles chez les veaux vaccinés, lesquelles se situaient dans les valeurs normales. Les veaux témoins ont éliminé du VRSB pendant plusieurs jours après l’infection alors que les VRSB n’étaient pas détectés dans les prélèvements provenant des voies nasales profondes des veaux vaccinés. En résumé, les résultats indiquent que ce vaccin inactivé contre le VRSB assure une protection clinique contre une infection expérimentale avec le virus virulent 27 jours après la vaccination et diminue significativement la prévalence et la sévérité des lésions pulmonaires. L’efficacité était semblable à celle rapportée pour d’autres vaccins commerciaux inactivés et vivants modifiés contre le VRSB.</p><p><italic>(Traduit par Docteur André Blouin)</italic></p></trans-abstract></article-meta></front></pmc><affiliations><list></list><tree><noCountry><name sortKey="Ellis, John A" sort="Ellis, John A" uniqKey="Ellis J" first="John A." last="Ellis">John A. Ellis</name><name sortKey="Rhodes, Carrie" sort="Rhodes, Carrie" uniqKey="Rhodes C" first="Carrie" last="Rhodes">Carrie Rhodes</name><name sortKey="Waldner, Cheryl" sort="Waldner, Cheryl" uniqKey="Waldner C" first="Cheryl" last="Waldner">Cheryl Waldner</name><name sortKey="West, Keith H" sort="West, Keith H" uniqKey="West K" first="Keith H." last="West">Keith H. West</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000696 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 000696 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Pmc
|étape= Checkpoint
|type= RBID
|clé= PMC:1082864
|texte= Efficacy of a saponin-adjuvanted inactivated respiratory syncytial virus vaccine in calves
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:15825518" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a CovidV1
| This area was generated with Dilib version V0.6.33. |  |